The American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and Asociación Latinoamericana de Tórax have issued an update to their joint guidelines for the diagnosis and management of adult patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), as well as pulmonary fibrosis in patients with other interstitial lung diseases.
The guidelines were issued by a multidisciplinary committee of experts in interstitial lung disease as well as methodologists and patient representatives. They updated radiological and histopathological criteria for IPF and PPF by consensus. In addition, they used systematic reviews and evidence-based recommendations based on the GRADE approach to answer questions about transbronchial lung cryobiopsy, genomic classifier testing, antacids, and antireflux surgery for IPF and about nintedanib and pirfenidone for PPF.
Nuformix plc (LON:NFX) is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology using drug repurposing.
